Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

SERA vs INVA vs NTRA vs PRGO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SERA
Sera Prognostics, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$73M
5Y Perf.-82.9%
INVA
Innoviva, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.93B
5Y Perf.+60.8%
NTRA
Natera, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$31.16B
5Y Perf.+91.9%
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.61B
5Y Perf.-75.6%

SERA vs INVA vs NTRA vs PRGO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SERA logoSERA
INVA logoINVA
NTRA logoNTRA
PRGO logoPRGO
IndustryMedical - Diagnostics & ResearchBiotechnologyMedical - Diagnostics & ResearchDrug Manufacturers - Specialty & Generic
Market Cap$73M$1.93B$31.16B$1.61B
Revenue (TTM)$57K$424M$2.31B$4.18B
Net Income (TTM)$-32M$504M$-208M$-1.82B
Gross Margin-191.2%76.2%64.8%34.2%
Operating Margin-642.4%14.8%-13.4%-4.1%
Forward P/E11.9x5.6x
Total Debt$2M$269M$214M$3.97B
Cash & Equiv.$4M$551M$1.08B$532M

SERA vs INVA vs NTRA vs PRGOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SERA
INVA
NTRA
PRGO
StockJul 21May 26Return
Sera Prognostics, I… (SERA)10017.1-82.9%
Innoviva, Inc. (INVA)100160.8+60.8%
Natera, Inc. (NTRA)100191.9+91.9%
Perrigo Company plc (PRGO)10024.4-75.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: SERA vs INVA vs NTRA vs PRGO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: INVA leads in 3 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Natera, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. PRGO also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
SERA
Sera Prognostics, Inc.
The Secondary Option

SERA lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
INVA
Innoviva, Inc.
The Defensive Pick

INVA carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.

  • Lower volatility, beta 0.13, Low D/E 22.9%, current ratio 14.64x
  • Beta 0.13, current ratio 14.64x
  • 118.9% margin vs SERA's -563.9%
  • Beta 0.13 vs SERA's 1.56
Best for: sleep-well-at-night and defensive
NTRA
Natera, Inc.
The Growth Play

NTRA is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 35.9%, EPS growth 0.7%, 3Y rev CAGR 41.1%
  • 20.9% 10Y total return vs INVA's 94.9%
  • 35.9% revenue growth vs PRGO's -2.8%
  • +37.3% vs PRGO's -51.2%
Best for: growth exposure and long-term compounding
PRGO
Perrigo Company plc
The Income Pick

PRGO is the clearest fit if your priority is income & stability.

  • Dividend streak 10 yrs, beta 1.18, yield 9.8%
  • Better valuation composite
  • 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthNTRA logoNTRA35.9% revenue growth vs PRGO's -2.8%
ValuePRGO logoPRGOBetter valuation composite
Quality / MarginsINVA logoINVA118.9% margin vs SERA's -563.9%
Stability / SafetyINVA logoINVABeta 0.13 vs SERA's 1.56
DividendsPRGO logoPRGO9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)NTRA logoNTRA+37.3% vs PRGO's -51.2%
Efficiency (ROA)INVA logoINVA32.4% ROA vs SERA's -30.9%, ROIC 14.2% vs -46.2%

SERA vs INVA vs NTRA vs PRGO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SERASera Prognostics, Inc.

Segment breakdown not available.

INVAInnoviva, Inc.
FY 2025
Royalty
57.5%$236M
Product
41.8%$172M
License And Other Revenue
0.7%$3M
NTRANatera, Inc.
FY 2025
Product
99.6%$2.3B
Licensing and other
0.4%$10M
PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B

SERA vs INVA vs NTRA vs PRGO — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLINVALAGGINGSERA

Income & Cash Flow (Last 12 Months)

INVA leads this category, winning 5 of 6 comparable metrics.

PRGO is the larger business by revenue, generating $4.2B annually — 73305.3x SERA's $57,000. INVA is the more profitable business, keeping 118.9% of every revenue dollar as net income compared to SERA's -563.9%. On growth, NTRA holds the edge at +39.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSERA logoSERASera Prognostics,…INVA logoINVAInnoviva, Inc.NTRA logoNTRANatera, Inc.PRGO logoPRGOPerrigo Company p…
RevenueTrailing 12 months$57,000$424M$2.3B$4.2B
EBITDAEarnings before interest/tax-$36M$86M-$310M$58M
Net IncomeAfter-tax profit-$32M$504M-$208M-$1.8B
Free Cash FlowCash after capex-$28M$181M$97M$108M
Gross MarginGross profit ÷ Revenue-191.2%+76.2%+64.8%+34.2%
Operating MarginEBIT ÷ Revenue-642.4%+14.8%-13.4%-4.1%
Net MarginNet income ÷ Revenue-563.9%+118.9%-9.0%-43.5%
FCF MarginFCF ÷ Revenue-483.8%+42.8%+4.2%+2.6%
Rev. Growth (YoY)Latest quarter vs prior year-63.2%+10.6%+39.8%-7.2%
EPS Growth (YoY)Latest quarter vs prior year+15.0%+4.0%+185.4%-56.4%
INVA leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

PRGO leads this category, winning 4 of 6 comparable metrics.

On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than INVA's 8.1x.

MetricSERA logoSERASera Prognostics,…INVA logoINVAInnoviva, Inc.NTRA logoNTRANatera, Inc.PRGO logoPRGOPerrigo Company p…
Market CapShares × price$73M$1.9B$31.2B$1.6B
Enterprise ValueMkt cap + debt − cash$72M$1.7B$30.3B$5.1B
Trailing P/EPrice ÷ TTM EPS-2.87x6.91x-144.62x-1.14x
Forward P/EPrice ÷ next-FY EPS est.11.91x5.56x
PEG RatioP/E ÷ EPS growth rate0.67x
EV / EBITDAEnterprise value multiple8.10x7.42x
Price / SalesMarket cap ÷ Revenue905.27x4.55x13.51x0.38x
Price / BookPrice ÷ Book value/share1.21x1.65x17.55x0.55x
Price / FCFMarket cap ÷ FCF9.88x285.53x11.12x
PRGO leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

INVA leads this category, winning 6 of 9 comparable metrics.

INVA delivers a 46.5% return on equity — every $100 of shareholder capital generates $46 in annual profit, vs $-51 for PRGO. SERA carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), INVA scores 5/9 vs SERA's 2/9, reflecting solid financial health.

MetricSERA logoSERASera Prognostics,…INVA logoINVAInnoviva, Inc.NTRA logoNTRANatera, Inc.PRGO logoPRGOPerrigo Company p…
ROE (TTM)Return on equity-41.0%+46.5%-15.3%-50.7%
ROA (TTM)Return on assets-30.9%+32.4%-10.6%-19.8%
ROICReturn on invested capital-46.2%+14.2%-36.1%+3.7%
ROCEReturn on capital employed-58.2%+12.4%-18.3%+4.3%
Piotroski ScoreFundamental quality 0–92554
Debt / EquityFinancial leverage0.03x0.23x0.13x1.35x
Net DebtTotal debt minus cash-$2M-$282M-$862M$3.4B
Cash & Equiv.Liquid assets$4M$551M$1.1B$532M
Total DebtShort + long-term debt$2M$269M$214M$4.0B
Interest CoverageEBIT ÷ Interest expense-12560.33x63.45x-25.21x-7.20x
INVA leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

NTRA leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in NTRA five years ago would be worth $21,587 today (with dividends reinvested), compared to $1,613 for SERA. Over the past 12 months, NTRA leads with a +37.3% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors NTRA at 60.6% vs PRGO's -25.2% — a key indicator of consistent wealth creation.

MetricSERA logoSERASera Prognostics,…INVA logoINVAInnoviva, Inc.NTRA logoNTRANatera, Inc.PRGO logoPRGOPerrigo Company p…
YTD ReturnYear-to-date-36.0%+14.7%-3.9%-13.5%
1-Year ReturnPast 12 months-20.0%+21.7%+37.3%-51.2%
3-Year ReturnCumulative with dividends-45.1%+95.2%+314.0%-58.1%
5-Year ReturnCumulative with dividends-83.9%+94.4%+115.9%-60.1%
10-Year ReturnCumulative with dividends-83.9%+94.9%+2089.4%-77.7%
CAGR (3Y)Annualised 3-year return-18.1%+25.0%+60.6%-25.2%
NTRA leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

INVA leads this category, winning 2 of 2 comparable metrics.

INVA is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than SERA's 1.56 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INVA currently trades 90.7% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSERA logoSERASera Prognostics,…INVA logoINVAInnoviva, Inc.NTRA logoNTRANatera, Inc.PRGO logoPRGOPerrigo Company p…
Beta (5Y)Sensitivity to S&P 5001.56x0.13x1.26x1.18x
52-Week HighHighest price in past year$4.09$25.15$256.36$28.44
52-Week LowLowest price in past year$1.37$16.52$131.81$9.23
% of 52W HighCurrent price vs 52-week peak+46.9%+90.7%+85.7%+41.2%
RSI (14)Momentum oscillator 0–10041.439.957.160.9
Avg Volume (50D)Average daily shares traded55K621K1.3M3.4M
INVA leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

PRGO leads this category, winning 1 of 1 comparable metric.

Analyst consensus: SERA as "Buy", INVA as "Buy", NTRA as "Buy", PRGO as "Hold". Consensus price targets imply 160.4% upside for SERA (target: $5) vs 19.4% for NTRA (target: $263). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.

MetricSERA logoSERASera Prognostics,…INVA logoINVAInnoviva, Inc.NTRA logoNTRANatera, Inc.PRGO logoPRGOPerrigo Company p…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyHold
Price TargetConsensus 12-month target$5.00$37.67$262.50$20.00
# AnalystsCovering analysts5102736
Dividend YieldAnnual dividend ÷ price+9.8%
Dividend StreakConsecutive years of raises010
Dividend / ShareAnnual DPS$1.15
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.2%0.0%0.0%
PRGO leads this category, winning 1 of 1 comparable metric.
Key Takeaway

INVA leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 2 (Valuation Metrics, Analyst Outlook).

Best OverallInnoviva, Inc. (INVA)Leads 3 of 6 categories
Loading custom metrics...

SERA vs INVA vs NTRA vs PRGO: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is SERA or INVA or NTRA or PRGO a better buy right now?

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Sera Prognostics, Inc. (SERA) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SERA or INVA or NTRA or PRGO?

On forward P/E, Perrigo Company plc is actually cheaper at 5.

6x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — SERA or INVA or NTRA or PRGO?

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -83. 9% for Sera Prognostics, Inc. (SERA). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus SERA's -83. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SERA or INVA or NTRA or PRGO?

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Sera Prognostics, Inc. 's 1. 56β — meaning SERA is approximately 1137% more volatile than INVA relative to the S&P 500. On balance sheet safety, Sera Prognostics, Inc. (SERA) carries a lower debt/equity ratio of 3% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

05

Which is growing faster — SERA or INVA or NTRA or PRGO?

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SERA or INVA or NTRA or PRGO?

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -394. 2% for Sera Prognostics, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -450. 7% for SERA. At the gross margin level — before operating expenses — INVA leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SERA or INVA or NTRA or PRGO more undervalued right now?

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 11. 9x for Innoviva, Inc. — 6. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SERA: 160. 4% to $5. 00.

08

Which pays a better dividend — SERA or INVA or NTRA or PRGO?

In this comparison, PRGO (9.

8% yield) pays a dividend. SERA, INVA, NTRA do not pay a meaningful dividend and should not be held primarily for income.

09

Is SERA or INVA or NTRA or PRGO better for a retirement portfolio?

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Sera Prognostics, Inc. (SERA) carries a higher beta of 1. 56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +94. 9%, SERA: -83. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SERA and INVA and NTRA and PRGO?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SERA is a small-cap quality compounder stock; INVA is a small-cap high-growth stock; NTRA is a mid-cap high-growth stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while SERA, INVA, NTRA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SERA

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

INVA

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 71%
Run This Screen
Stocks Like

NTRA

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 19%
  • Gross Margin > 38%
Run This Screen
Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.9%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SERA and INVA and NTRA and PRGO on the metrics below

Revenue Growth>
%
(SERA: -63.2% · INVA: 10.6%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.